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Characterization of the effect of BRAF inhibitors on melanoma metabolism in
vitro and in vivo

Abstract
Vemurafenib is the first FDA-approved personalized treatment for metastatic melanoma
to show an improvement in survival. This serine threonine kinase inhibitor targets the
mutated BRAF V600E protein, which occurs in approximately 50% of melanomas. The
downstream effect of BRAF V600E blockade is inhibition of cell proliferation. Little is
known about the effect of vemurafenib on glucose metabolism in melanoma cells. The
Warburg effect, or the use aerobic glycolysis to generate energy and building blocks for
cell proliferation, is a hallmark of cancer. Normal cells, in contrast, metabolize glucose
through oxidative phosphorylation in the presence of oxygen and through glycolysis in
anaerobic environments. Vemurafenib decreases glucose uptake in sensitive human
melanoma cell lines but not in intrinsically resistant lines or lines that have been passaged
to become resistant. The Braf/Pten mouse model of melanoma shows no major decrease
in glucose uptake with treatment with PLX4720, an analog of vemurafenib, of up to 28
days perhaps because PTEN deletion removes the negative feedback on the PI3K/mTOR
pathway of cell metabolism. The decrease in uptake seen in vitro is associated with a
decrease in hexokinase (HK) activity, which is required for entrapment of glucose as
glucose-6-phosphate inside the cell, but not with significant changes in mRNA levels of
glucose transporters or hexokinases (GLUT1, GLUT2, GLUT3, HK1, or HK2). The
global effect of vemurafenib on glucose metabolism is decreased flux through glycolysis
as shown by decreased lactate levels. These observations indicate vemurafenib targets the
deregulated metabolism of human melanoma cells. This finding may lead to the
discovery and development of novel therapeutics that specifically target the abnormal
metabolism of cancer cells.
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INTRODUCTION

Molecular Pathogenesis and Staging of Melanoma
Melanoma is a malignancy of the pigment-producing cells of the skin called
melanocytes. Two models of melanoma progression exist: one predicts melanoma
formation from single cancer-prone melanocytes and another one predicts melanoma
formation from malignantly transformed nevi1. The latter, known as the Clark model,
depicts a continuous process of malignant transformation going from melanocyte to
nevus with the subsequent development of dysplasia, hyperplasia, invasion, and
metastasis (Figure 1).

Figure 1. Biologic Events in the Progression of Melanoma. A benign nevus undergoes molecular changes that
eventually lead to a premalignant dysplastic nevus, a melanoma in radial-growth phase, a melanoma in verticalgrowth phase, and finally metastatic melanoma1.
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The mitogen activated protein kinase (MAP kinase) pathway is an important
pathway for cell proliferation and melanomagenesis (Figure 2). It begins with a
transmembrane receptor tyrosine kinase, which when bound by a growth factor,
phosphorylates NRAS. Activated NRAS triggers a cascade of serine/threonine kinase
phosphorylations. The main kinases of this cascade are RAF, MEK, and ERK. Once
activated, ERK phosphorylates other kinases and gene regulatory proteins. By
transmitting the signal downstream, activated ERK drives transcription of genes required
for cell proliferation.

Figure 2. Mitogen Activated Protein Kinase Pathway of Cell Proliferation. Binding of growth factors to receptor
tyrosine kinases on the surface of the cell activate an intracellular signaling cascade that involves RAS, RAF,
MEK, and ERK.
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BRAF is a serine/threonine tyrosine kinase of the MAP kinase signaling pathway
of cell proliferation. This kinase plays an important role in melanocytic neoplasias2.
BRAF activating mutations occur in approximately 50% of melanomas and more than
90% of these mutations result in substitution of valine for glutamic acid at the 600th
amino acid (V600E)3, 4.
Mutations in NRAS have been found in malignant melanoma5-7. A case-control
study of melanoma and benign melanocytic nevi showed that 5.9% of nevi carry
mutations in NRAS, compared to 5.2% of melanomas8. More recently, a systematic
review of the melanoma literature revealed that the frequency of NRAS mutations in
melanomas is much higher, at 28%4. Ultraviolet radiation appears to play a role in the
induction of NRAS mutations, as most tumors carrying these genetic changes are located
in areas exposed to the sun9-11. There is, however, conflicting evidence for the role of UV
radiation in NRAS mutagenesis.
The mutated genes of the MAP kinase pathway, known as oncogenes because
they stimulate the development of cancer, also activate counterregulatory pathways that
inhibit cell proliferation in nevi, leading to growth arrest or senescence (i.e., oncogeneinduced senescence, or OIS). Senescence can be caused by various stresses, including
oncogene activation, telomere dysfunction, oxidative stress, DNA damage, cytotoxic
drugs, and cell culture12. Teleologically, senescence represents an evolutionary
gatekeeper against unwanted cancer formation. OIS has been shown to be an important
mechanism of growth arrest in oncogenically stressed cells13. Loss of OIS through
mutations in tumor suppressive pathways is postulated to allow oncogene-driven
malignant progression of nevi to melanoma. Two main pathways have been identified:
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p16INK4a-RB (retinoblastoma) and ARF-p5314. As expected, these two pathways are
often mutated in cancer14-17.
As part of the p16INK4a-RB pathway, the p16 (INK4) protein inhibits cell-cycle
progression in response to stress by blocking the formation of an active cyclin D1-Cdk4
complex. When p16 is inactive or absent, the active cyclin D1-Cdk4 complex
phosphorylates the retinoblastoma protein (Rb), rendering it nonfunctional.
Phosphorylated Rb releases the gene regulatory protein E2F, allowing expression of Sphase genes and progression of the cell cycle even in the context of damaging
environmental or intrinsic stressors.
The tumor suppressor protein p53 is mutated in about half of all human cancers,
making it a paramount gene in human cancer. The protein is involved in cell cycle
control, apoptosis, and maintenance of genetic stability. Oncogene-driven cell
proliferation stimulates the ARF protein, which then activates p53. DNA damage may
also stimulate p53 activation. Activated p53 induces the cell to commit suicide by
apoptosis or blocks cell division until the damage is repaired. The p53 protein inhibits
cell cycle progression by binding to DNA and inducing transcription of the CDKN1A
(p21) gene. The p21 protein binds to Cdk complexes, preventing the cell from entering Sphase and replicating its DNA.
Tissue markers for senescence include senescence-associated β-galactosidase
(SA-β-Gal), p16, p53, and p21. Staining of cells or tissue sections with the chromogenic
substrates X-gal or fluorescein di-β-d-galactopyranoside (FDG) for the detection of SAβ-Gal activity is the most widely used assay for the detection of OIS. Enzymatic activity
is derived from the increased lysosomal content of senescent cells; its biological
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significance, however, is still uncertain. Levels of p16, p53, and p21 can be measured by
means of immunohistochemistry and Western blotting.
Several studies of melanocytic neoplasia provide evidence that OIS is partly
responsible for the growth-arrested state of nevi and that loss of senescence-inducing
signaling pathways is associated with progression to melanoma. Normal human
melanocytes transduced with the oncogene BRAFV600E show early growth followed by
arrest after 21 days of culture18. Growth arrest correlated with SA-β-galactosidase
activity and elevated levels of p16. Human melanocytic nevi, irrespective of BRAF
mutational status, also display these markers and lack staining for the proliferation
marker Ki-67 on immunohistochemistry. These findings are consistent with the OIS
hypothesis of nevi.
Immunohistochemical comparison of benign compound nevi, dysplastic nevi, and
melanomas has also shed light on the role of the senescence-inducing pathways (e.g.
p16INK4a-RB and ARF-p53) in melanoma development and progression19. Benign
compound nevi show SA-β-galactosidase reactivity and intense p16 nuclear staining,
whereas p53 and p21 are not detectable. Dysplastic nevi, in contrast, showed less
extensive staining for p16 than benign compound nevi. Furthermore, staining was limited
to the cytoplasm, a pattern that is associated with dysfunctional p16. A proportion of nevi
showed pockets of p53-positive cells, often without p21, suggesting that benign nevi are
in a p16-dependent senescent state whereas dysplastic areas of nevi may still be
proliferating. Supporting this hypothesis, nevi from patients with a mutation that inhibits
nuclear translocation of p16, an event required for fully functional p16, tend to be large
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and of atypical appearance20. Furthermore, the tumor suppressors p21 and p53 are
expressed widely in these nevi.
Melanomas showed a few areas of immunoreactivity to p21 and p53, typically at
the edges of the lesion, with the bulk of the nodule being negative. Likewise, most areas
lacked detectable levels of p16, a finding more common in vertical growth-phase (VGP)
melanomas compared to radial growth-phase (RGP) melanomas. Although the staining
pattern of p21, p53, and p16 was similar between dysplastic nevi and the edges of
melanomas, the latter showed more intense reaction to CHK2, a checkpoint kinase that
mediates p53 activation on DNA damage and p53-dependent senescence. The edges of
melanomas may represent residual senescent regions, namely nevi.
A study using a mouse model of melanoma showed that p16 might play a less
prominent role in OIS than originally thought21. Mice harboring the BRAFV600E mutation
developed nevi regardless of the mutational status of CDKN2A (p16). This means that
nevi in CDKN2A-null mice entered senescence through an alternative tumor suppressive
pathway. Furthermore, tumors in mice carrying wild-type CDKN2A retained nuclear
expression of p16, suggesting that, in contradiction with other studies, disruption of the
p16INK4a-RB pathway is not necessary for melanoma progression. However, the study
showed that CDKN2A-null mice were more likely to develop melanomas than wild-type
CDKN2A mice (80% vs. 54% at 12 months). In addition, melanomas developed earlier in
the CDKN2A-null mice than in the wild type mice (50% of mice developed tumors at 7
months vs. 12 months). Finally, tumors in the CDKN2A-null mice were multiple whereas
the wild type mice developed single tumors. These results suggest p16 increases tumor
penetrance and decreases latency.
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A biopsy of clinically suspicious lesions, which are those showing asymmetry,
irregular borders, variation in color, diameter of greater than 6mm, and recent evolution
in appearance (ABCDE criteria), provides histologic confirmation of cutaneous
melanoma22. According to the American Joint Committee on Cancer, staging of
melanoma is based on maximal thickness of the tumor (T), presence or absence of
microscopic ulceration, the number and size of involved lymph nodes (N), and the
presence or absence of metastasis (M) (Tables 1 and 2)23.
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Treatments of Metastatic Melanoma
One American dies from melanoma almost every hour 24. Patients with metastatic
disease have a poor prognosis, with a median survival of <1 year

23

. Durable responses

are achieved in <10% of patients with metastatic melanoma treated with high-dose
interleukin-2 25. Ipilimumab (CTLA4 blocking antibody) has shown a survival benefit in
patients with metastatic melanoma, but long-term benefit was observed for only an
additional 10% of patients compared with control arm therapy in randomized, phase III
trials 26, 27. New treatments are needed.
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The increased knowledge about the molecular pathogenesis of melanoma has
opened the door to a personalized approach to the treatment of melanoma. BRAF
mutations have been found in ∼50% of melanomas, and most of these mutations result in
a substitution of glutamic acid for valine at the 600th amino acid of the BRAF protein
chain (V600E) 3. BRAF is a kinase that is part of the BRAF→MEK→ERK mitogenactivated protein kinase (MAPK) pathway of cell proliferation. The mutated kinase is
constitutively active and, in combination with other molecular oncogenic changes, results
in unregulated cell proliferation. In clinical trials, the selective BRAF inhibitor
vemurafenib (formerly known as PLX4032, RG7204, and RO5185426) produced
complete or partial tumor regression in most patients 28
Despite the promising results of these trials and the demonstrated clinical benefit,
responses are short-lived in many patients as a result of mechanisms that are not fully
understood. Some studies have shed light on the molecular correlations of drug resistance
(Figure 3). Melanoma cell lines treated with BRAF inhibitors show rebound
phosphorylated ERK (pERK) activation and escape from BRAF inhibition 29. Second-site
mutations that confer resistance have not been observed in BRAF to date 30. It is crucial
to gain a thorough understanding of the underlying mechanisms so that we can develop
novel strategies to circumvent resistance and achieve more prolonged responses.
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Figure 3. Mechanisms of Resitance to Vemurafenib. Various mechanisms of resistance have been elucidated.
Some depend on the MAP kinase pathway while others work independently of this pathway.

Clinical trials for vemurafenib

The current treatments for metastatic melanoma (i.e., interleukin-2 and
dacarbazine) are largely ineffective because they provide no improvement in overall
survival

31

. Dacarbazine in particular has a response rate of only 15% to 20%. The

discovery that >50% of melanomas harbor a mutation in the BRAF gene heralded the
development of targeted therapies against the corresponding mutant, activated protein 3.
The small-molecule BRAF inhibitor vemurafenib showed promising results in a
phase I trial

28

. This multicenter phase I trial consisted of 2 phases: a dose-escalation

phase and an extension phase. In the dose-escalation phase, investigators determined the
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recommended extension phase and phase II dose to be 960 mg twice daily. Higher doses
than this resulted in intolerable fatigue, rash, and arthralgias. Another common adverse
event was squamous cell carcinoma, keratoacanthoma-type. These well-differentiated
skin tumors have low invasive potential and no metastatic potential, and they can be
easily excised. The purpose of the extension phase was to determine the response rate
according to Response Evaluation Criteria in Solid Tumors (RECIST) in patients with
metastatic melanoma harboring the BRAF V600E mutation. Patients with brain
metastases were excluded from the study. Of the 32 patients in the extension cohort, 26
(81%) responded to treatment, with 68% of all patients having responses that were
sufficiently durable to be confirmed on subsequent scans. Two patients showed a
complete response, and 24 showed partial responses. Although some responses are
transient, with a median progression-free survival (PFS) time of ∼7 months (including
both responders and nonresponders), some patients show continued response for >2 years
32

.
The single-arm, multicenter, open-label phase II trial known as BRIM2 had a

primary endpoint of overall response rate, with a target of 20%, and secondary endpoints
of duration of response, PFS, and overall survival

32

. A total of 132 previously treated

patients with BRAFV600E-positive metastatic melanoma were enrolled in the study. A
companion diagnostic assay co-developed with vemurafenib, known as the cobas 4800
BRAF V600E Mutation Test (Roche Molecular Diagnostics), was used to determine the
BRAF mutational status of patients enrolled in the study. All patients were treated with
960 mg of vemurafenib twice daily until disease progression occurred. At the time of
analysis, the median follow-up was 7 months. With a response rate of 52% (62/132),
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consisting of 59 partial responses and 3 complete responses, the trial met its primary
endpoint. The median duration of response was 6.8 months, and the median PFS was 6.2
months. Consistent with the phase I trial, the most common side effects (>25%) were
rash, fatigue, and arthralgias. The most common grade 3 adverse event was cutaneous
squamous cell carcinoma (24.2%), which was excised without interfering with the trial.
An additional study was conducted to investigate whether vemurafenib is
associated with improved survival compared with dacarbazine, the standard of care. This
study, a global, randomized, open-label, controlled, multicenter phase III trial known as
BRIM3, accrued 675 untreated patients with BRAFV600E-positive metastatic melanoma 33.
The study met the primary endpoints of showing improvement in overall survival and
PFS at the time of the interim analysis, which occurred 1 month after the last patient was
accrued. With a median follow-up of just over 3 months, the interim analysis revealed
that the vemurafenib group achieved a 6-month overall survival of 84%, compared with
64% in the dacarbazine group. On the basis of these extraordinary results, patients in the
dacarbazine group were allowed to switch immediately to the vemurafenib group. The
median PFS was 5.3 months for vemurafenib compared with 1.6 months for dacarbazine.
Consistent with previous trials, the response rate of vemurafenib was 48% compared with
5% for dacarbazine, and the grade 3 or worse adverse effects consisted primarily of
arthralgias (3%), rash (8%), fatigue (2%), and cutaneous squamous cell carcinomas or
keratoacanthoma (20%).
Vemurafenib is the first personalized treatment for metastatic melanoma to show
an improvement in overall survival, and it was approved by the U.S. Food and Drug
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Administration in 2011.
Metabolism and Cancer
Cancer is characterized by uncontrolled cell proliferation. Recently, deregulated
metabolism has been identified as an emerging hallmark of cancer34. Alterations in
energy metabolism are necessary to fuel the rapid cell growth and division of malignant
cells. Normal cells utilize glucose in two different ways depending on the availability of
oxygen. In the presence of oxygen, normal cells metabolize glucose through glycolysis to
pyruvate in the cytosol and then shunt it to the mitochondria for oxidative
phosphorylation. In the absence of oxygen, normal cells break down glucose to lactate
via glycolysis and fermentation. Cancer cells, in contrast, partially reprogram their
metabolism to increase conversion of pyruvate to lactate irrespective of oxygen
availability. The metabolism of glucose through glycolysis with the production of lactate
is known as aerobic glycolysis.
To allow for increased lactate production and the maintenance of ATP synthesis,
cancer cells markedly upregulate glucose uptake, in part by increasing expression of
glucose transporters, such as GLUT135-37. This observation forms the basis for visualizing
glucose uptake using positron emission tomography (PET) with a radiolabeled analog of
glucose, specifically

18

F-fluorodeoxyglucose, as a reporter. Another glucose analog that

is used to study glucose metabolism is the fluorescence analog called 2-[N-(7-nitrobenz2-oxa-1,3-diazol-4-yl)amino]-2-deoxyglucose

(2-NBDG)

38

.

This

analog

is

phosphorylated by hexokinases but is not further metabolized.
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Increased glycolysis, while generating less ATP per glucose molecule than
oxidative phosphorylation, allows for the production of metabolic intermediates for
various biosynthetic pathways, including those of amino acids and nucleosides. The
result is an increased availability of building blocks for proteins and nucleic acids to
assemble organelles and form new cells.
The PI3K-mTOR pathway is an important pathway for metabolism, both in
normal and cancer cells. For this reason, multiple clinical trials of agents that target the
pathway are currently ongoing39. Activation of the pathway can involve binding of
insulin-like growth factors (IGFs) to IGF receptors. This event activates phosphoinositide
3-kinase (PI3K), which after a number of steps leads to activation of the mammalian
target of rapamycin (mTOR). The tumor suppressor PTEN negatively regulates PI3K
activation. The mTOR protein plays a central role in cell metabolism by regulating
protein translation (Figure 4).
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Figure 4. PI3K-mTOR pathway. Binding of insulin-like growth factors to membrane receptors leads to
activation of the PI3 kinase, leading to conversion of PI2P into PI3P. PI3P activates PDK1, which
phosphorylates AKT. AKT activates mTOR, promoting protein synthesis40.

Cell metabolism may play an important role in measuring responses to targeted
cancer therapies. A study that evaluated FDG-PET responses to vemurafenib in BRAFmutant advanced melanoma showed a trend for patients with greater reductions in uptake
of FDG to have longer progression-free survival41. At the same time, there was no
relationship between best response according to RECIST criteria and progression-free
survival.
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STATEMENT OF PURPOSE: SPECIFIC HYPOTHESIS AND SPECIFIC AIMS
OF THE THESIS
Hypothesis: vemurafenib targets the deregulated metabolism of cancer cells.
Aims:

-

Evaluate glucose uptake in human melanoma cell lines in vitro.

-

Evaluate glucose uptake in the Braf/Pten mouse model.

-

Characterize the mechanism of decreased glucose uptake.

-

Evaluate the global metabolic effect of treatment with vemurafenib.
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METHODS
In vitro Glucose Uptake Assay*
Cells from the lines 501Mel, YUKSI, YUKOLI, YURIF, YUCOT, YULACsensitive, and YULAC-resistant were cultured overnight in 2mL of Opti-MEM
supplemented with 10% FBS at 37°C and 5% CO2 in six-well plates at a density of
50,000 cells/mL. The YULAC-resistant line was generated by passaging the YULACsensitive line in medium containing 1 µM PLX4032 for several months. Each plate
corresponded to a specific time point. After overnight incubation, three wells were treated
with 3 µM PLX4032 (vemurafenib) and the other three wells were treated with control
vehicle of DMSO. For some cell lines, experiments were also performed with cells
treated with 300 nM MEK inhibitor and high concentrations of PLX4032 and MEK
inhibitor. At time 0, after treatment, cells were washed gently with PBS. Then they were
incubated in 150 µL of 300 µM 2-NBDG (Invitrogen) for 10 minutes and washed gently
three times with cold PBS. Next, they were visualized with a fluorescence microscope
equipped with a FITC filter and the intensity of the 2-NBDG signal was subjectively
scored using a scale from 0 (no signal, i.e. control wells) to 3 (maximum intensity). The
above steps were repeated for time points 7 hours, 9 hours, 12 hours, 24 hours, 48 hours,
and 72 hours.
Duplicate plates were made to measure the viability of the cells to ensure changes
in uptake were not due to cell death. Cell viability was measured by automatic trypan

*

Development and optimization of method as well as experiments on lines YULAC-sensitive and –
resistant performed by author; other cell lines evaluated by Nicholas Theodosakis.
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blue assay (Cell Countess).
Glucose Uptake In Vivo*
The Braf/Pten mouse model is an immunocompetent mouse model that relies on
the Cre-Lox recombination system42. Briefly, the Cre recombinant enzyme gene is fused
to an estrogen receptor gene. Expression of this construct is under control of the
tyrosinase promoter, ensuring expression is limited to melanocytes. The Cre-ER fusion
protein is inactive until 1 µL of 50 mg/mL 4-hydroxytamoxifen diluted six-fold in 100%
ethanol is applied to the skin of the mouse. The 4-hydroxytamoxifen binds to the estrogen
receptor and activates the Cre recombinase. Next, the Cre-ER enzyme recombines DNA
between loxP sites. Through this mechanism BrafWT transforms into BrafV600E and Pten is
deleted. Two weeks after induction a melanoma tumor begins to be visible at the site of
4-hydroxytamoxifen application.
Mice underwent melanoma induction this way and then were treated starting at
week 2 after induction with an analog of vemurafenib, PLX4720, for 0, 7, 14, 21, and 28
days. The PLX4720 was compounded in mouse chow to yield a dose similar to what is
achieved in human patients . At the given time points, the mouse was injected with 100
µL of 700 µM 2-NBDG retro-orbitally. Analogous to the use of 18F-fluorodeoxyglucose
for imaging of tumors using a PET scanner, the mouse was imaged using the Maestro in
vivo imaging system (CRI) and the Maestro imaging software for detection of glucose
uptake in the tumor 30 minutes after injection of 2-NBDG to allow distribution of the 2NBDG throughout the mouse’s body and tumor. The mouse was anesthetized in an
*

Performed by author
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isoflurane chamber for injection of 2-NBDG and imaging. The images were acquired and
analyzed as outlined in the system’s instructions manual.
Quantitative RT-PCR*
The cDNA levels of GLUT1, GLUT3, HK1, HK2, and HK3 in YULAC
(sensitive) both under treatment with 3 µM PLX4032 (vemurafenib) and control were
measured by quantitative RT-PCR using the TaqMan® Gene Expression Assay and the
StepOneTM Real-Time PCR System.
Hexokinase Assay†
The hexokinase assay (Biomedical Research Service Center University at Buffalo,
State University of New York, Cat #: E-111) was performed by following the protocol
previously described. Briefly, cell lysis solution was added to 105-106 pelleted cells of the
cell lines YULAC-sensitive and 501Mel. The cell lines were incubated in 3 µM
PLX4032 or DMSO control for 3 days. Lysate was centrifuged and supernatant was
recovered for HK assay. Bradford protein assay was performed to determine sample
protein concentrations for normalization. The sample protein concentration was
normalized to 0.2-1 mg/mL by diluting in ice-cold cell lysis solution. Next, 10 µL of
sample for each cell line was added in triplicate to a 96-well microplate. The reaction was
initiated by adding 50 µL of working HK assay solution to each well. The plate was
covered and incubated at 37°C for 30 minutes. Subsequently, the reaction was stopped by
adding 50 µL of 3% acetic acid per well. Optical density was measured at 492 nm using a
*
†

Performed by author.
Performed by Nicholas Theodosakis
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microplate reader and compared between experimental conditions and cell lines by using
a two-tailed Student’s T-test.
Tritiated 3-O-Methylglucose Uptake Assay*
The purpose of this assay is to determine whether treatment with vemurafenib
decreases glucose uptake by affecting the function of the glucose transporter (by means
of translocation or inactivation) or by affecting the function of hexokinase (by
downregulation of expression or inactivation). The protocol was modified from the
literature 43,44,45.
Cells were seeded in 6-well plates at predetermined cell densities, 2 mL/well and
incubated for 1 day at 37°C, 5% CO2. Then they were incubated in 3 µM vemurafenib (3
wells) or vehicle (3 wells) for 72 hours. Duplicate plates were generated for cell counting
since control vs. treated wells have different cell densities at 72 hours. At 72 hours, cells
were washed with 1 mL PBS followed by the addition of 1 mL of PBS. Next, 10 µL of
tritiated 3-O-methylglucose stock solution (100X) were added and the plates were
incubated for 30 seconds, 60 seconds, and 3 minutes.
The 3-O-methylglucose stock solution was prepared as follows. A volume of 50
uL

of

[3H]3-O-methylglucose

(American

Radiolabeled

Chemicals,

cat.

No.

NET379001MC, 60-90 Ci/mmol, 1 mCi/ml in ethanol-water 9:1) was added to 450 µL of
1 g/L 3-O-methylglucose (3-O-methyl-D-glucopyranose; Sigma-Aldrich, cat. No.
101176252, 1 g – FW 194.18 g/mol) in PBS with Ca/Mg to make a 100X, 100 µCi/mL, 5
mM 3-O-methylglucose stock solution.
At the end of each time point, cells were washed three times with 500 µL ice-cold
*

Performed by author
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PBS supplemented with 100 µM phloretin. Phloretin is a compound that blocks glucose
transporters and ensures the level of radioactivity measured from the samples comes from
the intracellular stores of tritiated 3-O-methylglucose. Next, 300 µL of modified RIPA
buffer was added for cell lysis and the plate was incubated for 10 min. The entire cell
lysate was transferred into a scintillation vial containing 3 mL of liquid scintillation
cocktail (ICN). To collect any remaining lysate, 300 µL PBS buffer was added into each
well for washing and then this buffer was transferred into the corresponding scintillation
vial. A second wash and collection of buffer was performed followed by vortexing of the
scintillation vial (total 3.9 mL) for a few seconds.
The radioactivity associated with the cells was quantified using a scintillation
counter (the “counts per minute or cpm of each scintillation vial). A volume consisting of
600 µL PBS, 300 µL modified RIPA buffer, and 3 mL of scintillation fluid served as a
blank and 10 µL of 3-O-MG stock solution served as the external standard.
Metabolic Flux Cell Labeling*
Melanoma cells were labeled with 13C-glucose and – glutamine as previously
described46.
Briefly, melanoma cells were seeded into 6-well plates such that at the end of the labeling
period they were at confluency (plated 2 mL at density of ~75,000 cells/mL in OptiMEM with 10% v/v FBS, 1% v/v pen/strep and supplemented with 3 µM PLX4032 in
treated wells and DMSO in control wells). For each condition, cells were seeded into 4
wells (3 for gas chromatography-mass spectroscopy analysis, 1 for protein
determination). After 24 hours to allow cell to attach to plate and following incubation

*

Performed by author
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for two days, 1 mL of medium was saved. The sample was centrifuged to remove floating
cells and the supernatant was collected and then shipped. Next, the growth medium was
replaced with 2mL/well of glucose labeling medium (MEM--Cellgro 15-010: 1 g/L
glucose, no glutamine--supplemented with 1 g/L [U-13C6] glucose, 10% v/v FBS, 1mM
L-glutamine, 1% v/v pen/strep, 1% v/v MEM vitamins, 1X NEAA) or 2mL/well of
glutamine labeling medium (MEM--Cellgro 15-010: 1 g/L glucose, no glutamine-supplemented with 1 g/L unlabeled glucose, 10% v/v FBS, 0.5 mM unlabeled Lglutamine, 0.5 mM [U-13C5] L-glutamine, 1% v/v pen/strep, 1% v/v MEM vitamins, 1X
NEAA). Medium to be added to treated cells was supplemented with 3 µM PLX4032.
Cells were incubated in the labeling media for 8 hours and 24 hours.
For extraction, 1mL of medium from labeled cells was saved. Floating cells were
removed by centrifugation and the supernatant was collected and shipped. Cells were
collected by trypsinization and spun down at 500 x g at 4°C. Cells were kept on ice after
they were harvested. Cells were resuspended in 1mL of ice-cold PBS and transferred into
Eppendorf tubes. Then they were spun down at 500 x g for 5 minutes and the PBS was
removed without disturbing the cell pellet. The cells were placed on dry ice for freeze
down. The frozen pellets were kept at -70°C. The frozen samples were then shipped on
dry ice overnight.
Shipments were sent to Sanford-Burnham at University of California-San Diego
for gas chromatography-mass spectrometry analysis (GC-MS) following a previously
described protocol46.
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RESULTS
2-NBDG in vitro uptake assay:
To evaluate the effect of vemurafenib treatment on glucose uptake melanoma
cells were exposed to the glucose analog 2-NBDG in vitro. The most sensitive cell line to
PLX4032, YULAC-sensitive, showed a gradual decrease in glucose uptake, starting at a
time between 7 and 9 hours. Uptake decreased to undetectable levels at 48 hours. In
contrast, the resistant counterpart showed no decrease in uptake (Figure 5). YUCOT,
another sensitive line showed decreased uptake as early as 9 hours after incubation in
PLX4032 (Figure 6). The moderately sensitive lines YUKOLI and YURIF showed minor
decrease in uptake at 72 and 24 hours, respectively. The resistant line YUKSI showed no
decrease in uptake while the other resistant line 501Mel showed a minor decrease in
uptake as early as 7 hours.
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Figure 5. Effect of PLX4032 on glucose uptake in human melanoma cell lines YULAC-sensitive and -resistant.
YULAC-sensitive is susceptible to the inhibitory effect of PLX4032 on glucose uptake. In contrast, acquired
resistance YULAC is not.
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Figure 6. Effect of PLX4032 on glucose uptake in the human melanoma cell lines YUCOT, YUKOLI, YURIF,
YUKSI, and 501Mel.
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In vivo glucose uptake assay
To evaluate the effect of treatment with vemurafenib on glucose uptake in
melanoma cells in vivo, a Braf/Pten mouse bearing a melanoma tumor was treated with
the vemurafenib analog, PLX4720, and imaged using the glucose analog 2-NBDG. No
definitive decrease in glucose uptake was observed in the melanoma tumor at 0, 7, 14, 21,
or 28 days after initiation of treatment with PLX4720 (Figure 7).
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Figure 7. Effect of the vemurafenib analog, PLX4720, on glucose uptake in the Braf/Pten mouse melanoma
model. No effect on glucose uptake was observed up to 28 days of treatment.

qRT-PCR levels
Given the delayed time-course of decrease in glucose uptake observed in vitro, it
was possible that vemurafenib decreased glucose uptake by inhibiting the transcription of
the genes required for glucose uptake, namely the glucose transporters and the
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hexokinases. To test this possibility quantitative RT-PCR was performed. The change in
mRNA levels of glucose transporter genes was not significant (data not shown). .

HK activity assay
Hexokinase phosphorylates glucose that enters the cell and converts it into
glucose-6-phosphate, a form that is trapped intracellularly. To investigate whether
vemurafenib decreases glucose uptake in melanoma cell lines by altering the function of
hexokinase, a hexokinase activity assay was performed. The hexokinase activity level
was halved in the YULAC-sensitive cell line (p<0.05) whereas no change was observed
in the most resistant line, 501Mel (Figure 8). The assay neither distinguishes among the
three hexokinases (HK1, HK2, and HK3) nor gives an indication as to the alteration that
results in the drop in activity level.
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Figure 8. Effect of treatment with vemurafenib on hexokinase activity level in the YULAC-sensitive and 501Mel
(resistant) human melanoma cell lines.
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3-O-Methylglucose Uptake Assay
To evaluate whether vemurafenib treatment decreases the number of glucose
transporters, a time-course of tritiated 3-O-methylglucose uptake was generated.
Hexokinase cannot phosphorylate this glucose analog. The uptake of 3-O-methylglucose
showed no difference between the control and treated samples in the YULAC-sensitive
line. In contrast, 501Mel showed increased uptake with treatment at 30 and 60 seconds
(p<0.05) (Figure 9). The mechanism for this increase is unclear.
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Figure 9. Time-course of tritiated 3-O-methylglucose uptake in YULAC-sensitive and 501Mel (resistant) human
melanoma cell lines treated with vemurafenib for 72 hours. The YULAC-sensitive line showed no change in the
level of surface transporters, as evidenced by the equal kinetics of 3-O-MG uptake between treated and control.
501Mel showed an increase in the level of glucose transporters, as evidenced by the increase in 3-O-MG uptake
at 30 and 60 seconds (p-value<0.5).
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Cell labeling
Labeling cells with 13C-glucose followed by quantification of proportion of
labeled metabolites, allows for the creation of a metabolic profile and for evaluation of
flux. The YULAC-sensitive line showed decreased flux of 13C through glycolysis to
lactate and alanine with treatment consisting of 3 µM PLX4032. This decrease in flux
was much less marked in the YULAC-resistant line. The production of lactate and
phosphoglyceraldehyde were slightly increased in the 501Mel cell lines. There were no
significant changes in the level of metabolites in the tricarboxylic acid cycle. Evaluation
of glutamine levels is out of the scope of this thesis.
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Figure 10. Metabolic profile of YULAC-sensitive, -resistant, and 501Mel before and after treatment with
vemurafenib. The YULAC-sensitive line shows a decrease in the level of lactate with treatment, indicating
decreased flux through glycolysis and possibly increased flux through the TCA cycle for oxidative
phosphorylation. A concomitant increase in TCA cycle metabolites, however, was not observed. Lactate levels
decreased slightly in YULAC-resistant and increased in 501Mel.
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DISCUSSION
The effect of kinase inhibitors on cell metabolism has previously been studied. In
particular, imatinib has been shown to decrease glucose uptake in BCR-ABL-positive
cells and inhibit glycolysis47. Gefitinib, an EGFR receptor inhibitor, has been shown to
inhibit glucose uptake in non-small cell lung cancer cell lines44. This study now shows
that vemurafenib, a serine threonine kinase inhibitor, decreases glucose uptake by what
appears to be a hexokinase-dependent mechanism and that this decrease in uptake may be
important for the mechanism of action of the drug. The first set of data shows that
treatment of sensitive cell lines (YULAC-sensitive, YUCOT, YURIF, YUKOLI) results
in decreased glucose uptake whereas treatment of acquired or intrinsically resistant cell
lines (501Mel, YULAC-resistant, YUKSI) does not. As confirmed by automatic trypan
blue assay (Cell Countess), the decrease in uptake is not accompanied by a significant
decrease in cell death (data not shown), indicating the result is not due to increased cell
death in the treated samples. Interestingly, the inhibitory effect of vemurafenib on
glucose uptake in the YULAC cell line is lost in the resistant counterpart, suggesting that
glucose uptake may play an important role in the mechanism of resistance to
vemurafenib. The decrease in uptake occurs between 7 and 9 hours in the YULAC
sensitive cell line. The time course of uptake decrease points toward particular
mechanisms. An immediate decrease in uptake would indicate a fast mechanism, such as
phosphorylation of the transporters with subsequent blockage of the transport pore, is
taking place. A delayed decrease, as was observed in this case, points toward a slow
mechanism, such as downregulation of DNA transcription or alteration of translational
efficiency.
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The Braf/Pten mouse model was used to investigate glucose uptake in vivo. The
melanoma tumor that forms in this model harbors a BrafV600E mutation and a PTEN
deletion. PTEN is an inhibitor of phosphoinositide-3-kinase, a key regulator of the PI3KmTOR pathway of cell metabolism. The absence of decreased glucose uptake in the
tumor after 7, 14, 21, and 28 days of treatment might indicate the genetic makeup of the
tumor renders the model resistant to decreases in glucose uptake. The absence of PTEN,
theoretically, leaves the PI3K-mTOR pathway without its main negative regulator,
possibly allowing glucose uptake to continue despite BRAF inhibition. Interestingly,
treatment with PLX4720 reduces tumor growth in these mice. This might indicate a
decoupling of growth arrest, through inhibition of cell proliferation via BRAF blockage,
and glucose uptake, through lack of negative feedback via PTEN in the PI3K-mTOR
pathway.
A decrease in glucose uptake can occur by either an effect on facilitative glucose
transporters on the surface of the cell or by an effect on the intracellular hexokinase
enzymes. The transporters allow passage of glucose into the cell. Hexokinase
phosphorylates glucose to form glucose-6-phosphate and traps the compound inside the
cell. The effect may be at the transcriptional (mRNA), translational (protein), or posttranscriptional level (protein modifications). More than one mechanism may be taking
place. For example, non-small cell lung cancer cell lines show decreased FDG uptake by
translocation of GLUT3 transporters from the plasma membrane to the cytosol and a
modest decrease in hexokinase activity44. GLUT3, also known as the neuronal-type
glucose transporter because of its preponderance in cells of the nervous system, has a
higher affinity for glucose than GLUT1,-2, or -4 and has at least a fivefold greater
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transport capacity than GLUT1 and -448. These properties and the neural origin of
melanocytes, namely neural crest cells, make GLUT3 a good candidate for the increased
glucose uptake observed in melanoma cell lines. So far, however, the results do not
confirm this hypothesis. In the case of chronic myelogenous leukemia, the decrease in
glucose uptake observed with imatinib treatment is caused by intracellular translocation
of GLUT1 transporters from the plasma membrane. Quantitative PCR showed changes in
mRNA levels of GLUT1, GLUT3, HK1, HK2, and HK3 but these were within the
margin of error. This indicates that although the time course is consistent with a
transcriptional event, other mechanisms are taking place.
A hexokinase activity assay revealed that treatment with vemuferanib results in
decreased hexokinase activity in the YULAC sensitive cell line but not in highly resistant
501Mel cell line, suggesting that vemurafenib decreases glucose uptake by a translational
or post-translational mechanism at the level of hexokinase. For example, vemurafenib
may inhibit translation of hexokinases. The three hexokinase isozymes differ in catalytic
and regulatory properties as well as subcellular localization49. Hexokinase I appears to be
constitutively expressed in a variety of cellular contexts. Hexokinases II is less abundant
in normal tissues, but may be overexpressed in cancer. In terms of localization, HK1 and
HK2 bind to the mitochondria and may be present in the cytoplasm whereas HK3 has a
predominantly perinuclear localization in many cell types.
The glucose analog 3-O-methylglucose can enter the cell through glucose
transporters but cannot be phosphorylated. As a result, a decrease in 3-O-MG in sensitive
cell lines upon treatment with vemurafenib would indicate an effect at the level of the
glucose transporters. No change was observed in 3-O-MG in YULAC-sensitive cell lines
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suggesting glucose transporters do not translocate into cytoplasmic vesicles or become
modified in a way that blocks their transport pores. The resistant cell line 501Mel,
however, showed an increase in 3-OMG uptake indicating that vemurafenib might
paradoxically enhance glucose uptake in this resistant line.
The metabolic profile of melanoma cell lines has previously been studied46.
Specifically, all the melanoma cell lines in that study exhibited the Warburg
phenomenon, which means they used more glucose and produced more lactate than
melanocytes under aerobic conditions. Other changes observed in the study were increase
in fermentation in both melanocytes and melanoma cells under hypoxic conditions, a
phenomenon known as the Pasteur effect. In this thesis, the metabolic profile of
melanoma cells was evaluated in the presence of vemurafenib. The global picture of
glucose metabolism in sensitive and resistant lines that this experiment generated showed
that vemurafenib decreases flux through glycolysis in the YULAC-sensitive but not in the
YULAC-resistant line as evidenced by the drop in lactate levels. Interestingly, 501Mel
shows a slight increase in lactate levels with vemurafenib treatment. This is consistent
with the increase in 3-O-methylglucose inflow observed with treatment in the 501Mel
line. Overall, these experiments support the hypothesis that vemurafenib induces a
metabolic profile in melanoma cell lines that is limited in glycolysis, reversing the
Warburg effect. The effect of vemurafenib on glutamine levels is out of the scope of this
thesis.
Future directions for this study include the corroboration of glucose uptake timecourse experiments with flow cytometry in vitro. While mRNA levels of the glucose
transporter were unchanged, Westerns blots will be important to analyze variation in
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protein levels. The localization of the glucose transporters might also be affected, despite
the data that showed no change in 3-O-MG uptake in the YULAC-sensitive line, and will
be studied with confocal microscopy. Given the variety of glucose transporters and
hexokinases, siRNA or shRNA experiments would be useful in evaluating the
contribution of each protein to glucose uptake.
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